Newsroom
Sorted by: Latest
-
United Utilities Water PLC UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: United Utilities Water Plc GBP 35,000,000.00 MATURING: 21-Nov-2047 ISIN: XS0275712049 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 21-May-2026 TO 21-Nov-2026 HAS BEEN FIXED AT 2.92 PCT DAY BASIS: 30/360 INTEREST PAYABLE VALUE 21-Nov-2026 WILL AMOUNT TO: GBP 728.83 PER GBP 50,000.00 DENOMINATION ...
-
Western Alliance 100 Brings Business Leaders Together to Build Connections, Broaden Perspectives and Advance Growth
PHOENIX--(BUSINESS WIRE)--Western Alliance Bank hosted its first Western Alliance 100, an invitation-only CEO strategic forum in Phoenix that brought together top clients and business leaders from across the country to explore the forces shaping business decisions and the opportunities ahead. President George W. Bush joined Western Alliance Chairman, President and CEO Kenneth Vecchione for a moderated conversation, while Duke’s legendary Coach K and experts in markets, technology and demographic...
-
Equity Release Funding 4 UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Equity Release Funding No4 Plc GBP 1,000,000.00 MATURING: 30-Jul-2049 ISIN: XS0197424400 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 30-Jul-2026 TO 30-Oct-2026 HAS BEEN FIXED AT 5.82 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 30-Oct-2026 WILL AMOUNT TO: GBP 73.32 PER GBP 5,000.00 DENOMINATION ...
-
Worthington Steel Confirms Its Kloeckner Strategy Following Shareholder Vote
COLUMBUS, Ohio--(BUSINESS WIRE)--Worthington Steel Confirms Its Kloeckner Strategy Following Shareholder Vote...
-
Ronald McDonald House New York’s Board of Associates Celebrates 15 Years of Leadership, Philanthropy and Community at Annual Soirée
NEW YORK--(BUSINESS WIRE)--Hundreds of New Yorkers gathered at the Edison Ballroom on October 22, marking the 15th anniversary of Ronald McDonald House New York’s (RMH-NY) Board of Associates (BoA). The Annual Soirée brought together young professionals, alumni and supporters to celebrate the Board’s longstanding commitment to children and families facing pediatric cancer and other serious illnesses. Over the past 15 years, the Board of Associates has raised nearly $6.7 million through fundrais...
-
Equity Release Funding 4 UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Equity Release Funding No4 Plc GBP 16,500,000.00 MATURING: 30-Jul-2049 ISIN: XS0197424236 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 30-Jul-2026 TO 30-Oct-2026 HAS BEEN FIXED AT 5.52 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 30-Oct-2026 WILL AMOUNT TO: GBP 69.54 PER GBP 5,000.00 DENOMINATION ...
-
Equity Release Funding 4 UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Equity Release Funding No4 Plc GBP 61,000,000.00 MATURING: 30-Jul-2049 ISIN: XS0197423774 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 30-Jul-2026 TO 30-Oct-2026 HAS BEEN FIXED AT 4.62 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 30-Oct-2026 WILL AMOUNT TO: GBP 58.2 PER GBP 5,000.00 DENOMINATION ...
-
Equity Release Funding 4 UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Equity Release Funding No4 Plc GBP 215,000,000.00 MATURING: 29-Jul-2039 ISIN: XS0197423345 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 30-Jul-2026 TO 30-Oct-2026 HAS BEEN FIXED AT 4.22 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 30-Oct-2026 WILL AMOUNT TO: GBP 53.16 PER GBP 5,000.00 DENOMINATION ...
-
Mundipharma 公佈 ReSPECT 第三期研究進一步結果,在 IDWeek 2026 上以最新突破口頭報告形式發表
英國劍橋--(BUSINESS WIRE)--(美國商業資訊)-- Mundipharma 今日公佈全球第三期 ReSPECT 臨床試驗的進一步結果,該研究旨在評估 REZZAYO® (醋酸瑞扎芬淨)對接受異基因造血幹細胞移植 (allo-HSCT) 之成年患者預防侵入性真菌病 (IFD) 的效果。第三期研究結果今日於 IDWeek 2026 上以最新突破口頭報告形式發表。 報告在 2026 年 4 月發表之 ReSPECT 摘要結果基礎上透露進一步詳情,包括更多終點分析、構成無真菌存活 (FFS) 的組成部分、預先指定的敏感度分析,以及詳細的安全性結果。額外分析與先前公佈的摘要結果保持一致。 ReSPECT 為一項全球、多中心、隨機、雙盲第三期研究,402 名患者隨機接受瑞扎芬淨,200名患者則接受標準抗菌治療方案。一如先前公佈,研究已達主要終點,顯示瑞扎芬淨在 allo-HSCT 後第 90 日的 FFS 方面之於標準抗菌治療方案的非劣效性。 主要終點結果獲六項預先指定的敏感度分析佐證,該等分析涉及審視不明確結果的處理、IFD 的定義、隨機分層因素,以及非研究用全身性抗真菌治療的使...
-
ムンディファーマ、第III相ReSPECT試験の追加結果を公表、「IDWeek 2026」でレイト・ブレイキング口頭発表
イングランド、ケンブリッジ--(BUSINESS WIRE)--(ビジネスワイヤ) -- ムンディファーマは、同種造血幹細胞移植(allo-HSCT)を受ける成人患者における侵襲性真菌症(IFD)の予防を目的とした「 REZZAYO® 」(レザフンギン酢酸塩)を評価する国際共同第III相臨床試験ReSPECTの追加結果を発表しました。第III相試験の結果は、IDWeek 2026でレイト・ブレイキング口頭発表として報告されました。 今回の発表では、2026年4月に発表されたReSPECT試験のトップライン結果に続き、評価項目の追加解析、真菌フリー生存率(FFS)の構成要素、事前に規定された感度分析、安全性に関する詳細な結果など、さらに詳しい情報が示されました。追加解析の結果は、すでに発表されたトップライン結果と整合するものでした。 ReSPECTは、国際多施設共同の無作為化二重盲検第III相試験で、患者402人がレザフンギン群に、200人が標準抗微生物薬レジメン群に無作為に割り付けられました。すでに発表したとおり、同試験は主要評価項目を達成し、allo-HSCT後90日目のFFSにお...